Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Myelitis is a rare but well documented complication of therapeutic radiation exposure to the spinal cord and is characterized by delayed development of paresthesias, sensory changes and, in severe cases, progressive paresis and paralysis. Although accepted radiation tolerance limits for the spinal cord have successfully limited the incidence of this problem (45-50 Gy, in daily 1.8-2 Gy fractions), aggressive systemic therapy may render patients more susceptible to radiation-related neurotoxicity. We describe the case of a 38-year-old man with refractory non-Hodgkin's lymphoma who underwent matched sibling peripheral blood stem cell transplant following a conditioning regimen of cyclophosphamide (60 mg/kg x 2) and total body irradiation (120 cGy x 11). This was followed by delivery of 30.6 Gy involved-field radiation at 1.8 Gy/day to the mediastinum and left supraclavicular fossa for bulky residual tumor. Although maximum cumulative radiation dose to the spinal cord was less than 45 Gy, the patient subsequently developed progressive lower extremity weakness and MRI abnormalities of the spinal cord limited to the radiation field. This represents the second report in the literature of this unexpected complication, prompting a need to re-examine current guidelines for radiotherapy in the context of high-dose systemic treatment.
 ...
PMID:Radiation myelitis following allogeneic stem cell transplantation and consolidation radiotherapy for non-Hodgkin's lymphoma. 1154 53

Two cases of pyothorax-associated malignant lymphoma were reported. The presence of chronic tuberculous pyothorax after thoracoplasty and the development of non-Hodgkin's lymphoma on the chest wall are closely related. Both patients had suffered from tuberculous pyothorax for more than thirty years, and developed new painful chest wall tumors. CT and MRI delineated both malignant lymphoma and pyothorax. Gallium-67 accumulated strongly in malignant lymphoma, however did not in pyothorax. Gallium-67 scintigraphy was useful for detection of malignant lymphoma in both cases; therefore it could be a useful test for diagnosing of pyothorax-associated lymphoma.
 ...
PMID:[Usefulness of gallium-67 scintigraphy in diagnosing pyothorax-associated lymphoma]. 1145 88

FDG-PET is both able to provide information of lymphomatous organ involvement not available by conventional imaging techniques (US, CT, MRI) and to give reliable data otherwise obtainable only by using invasive procedures. As a whole body-screening technique, PET reduces diagnostic requirements and potential complications. Nevertheless the conventional imaging techniques are essential for the exact localisation and correct interpretation of PET findings. A number of factors that may produce false-positive results have to be taken into consideration, including post-treatment inflammatory changes and the sensitivity of the method in the setting of minimal residual disease. Despite its potential of a screening method being performed prior to other imaging procedures, PET is not yet established as a routine element for the primary staging of Hodgkin's disease and non-Hodgkin's lymphoma. Its value for re-staging is less doubtful due to the frequency of stage migration and possible changes in therapy related to the use of PET. Detailed cost-effectiveness studies are needed to assess the economic implications of an expanded use of PET in lymphoma therapy.
 ...
PMID:Positron emission tomography and lymphoma therapy. 1169 79

This study evaluates and compares the accuracy of positron emission tomography with 18F-fluoro-2-deoxyglucose (FDG-PET) and gallium-67 citrate (Ga-67) scintigraphy in identifying disease sites in patients with malignant lymphoma at initial diagnosis or relapse. Histology subgroups included low (n=5), intermediate (n=6), high-grade (n=5) non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) (n=14). Ann-Arbor staging included 7 patients in stage I, 8 in stage II, 9 in stage II, 6 in stage IV and 11 extra-nodal. In this study, before any therapy, 25 contemporaneous FDG-PET and Ga-67 scintigraphies were performed on patients with either NHL (16) or HD (14). One hundred and eleven sites of disease were correlated on a site-by-site basis in corresponding areas of FDG-PET and Ga-67 scintigraphy. Discordant FDG-PET and Ga-67 scintigraphic findings were correlated with CT/MRI and clinical evaluation. FDG-PET detected malignant lymphoma in 24/25 patients (sensitivity: 96.0%). There was a false-negative FDG-PET result in only 1 patient with low-grade gastric malignant lymphoma. Ga-67 scintigraphy detected malignant lymphoma in 18/25 patients (sensitivity: 72.0%). There were false-negative Ga-67 scintigraphic results in 4 cases with low-grade non-Hodgkin's lymphoma, 2 cases with bone or bone marrow involvement, and 3 smaller disease sites. FDG-PET upstaged 6 patients in whom Ga-67 scintigraphy detected disease sites partially. In imaging lymphoma prior to therapy, FDG-PET had a higher sensitivity and detected significantly more disease sites when compared with Ga-67 scintigraphy in the initial evaluation of this group of patients. Upstaging of patients with FDG-PET may result in a change in treatment strategy. However, evaluation of the final sensitivity, specificity and accuracy of these imaging modalities will need a further study with a larger patient number.
 ...
PMID:Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. 1183

We report a 36-year-old woman whose first MRI after developing symptoms of cervical nerve root irritation was normal. Eight months later, after progression to tetraparesis and demonstration of an extensive contrast-enhancing intramedullary lesion giving high signal on T2-weighted images, the diagnosis of lymphoblastic non-Hodgkin's lymphoma was made by biopsy. The lesion responded for a short time to corticosteroid medication, but later rapidly extended to the epidural soft tissues, probably due to a cerebrospinal fluid fistula. Despite radio-and chemotherapy, the patient survived only 7 months from histological diagnosis and 15 months from the onset of symptoms.
 ...
PMID:Primary CNS lymphoma in the spinal cord: clinical manifestations may precede MRI detectability. 1194 80

The objective of this study was to evaluate the feasibility and possible response to pre-radiation chemotherapy given to patients with central nervous system (CNS) relapse of systemic non-Hodgkin's lymphoma (NHL). Twenty-three consecutive adult patients with systenic NHL and first CNS relapse were evaluated by CSF cytology and neuroaxis MRI. Treatment was based on weekly high-dose methotrexate (HD-MTX) 3.5 g/m2 and weekly intra-CSF cytarabine (ARA-C). Oral procarbazine 100 mg/m2 days 2-15 was added to patients whose bone marrow reserve could tolerate this drug. Radiation therapy (RT) to the CNS was deferred in responding/stable CNS disease. All patients with leptomeningeal seeding, but without parenchymal involvement responded to treatment prior to RT with 33% achieving a complete response (CR). Concomitant response of systemic disease was noted in 36% of the cases with 9% CR. Addition of RT to the CNS did not significantly change the overall rate of CR. Progression free survival for CNS disease was 5 months and for systemic disease 2 months. All patients with parenchymal involvement responded to therapy prior to RT with only 9% achieving CR, and the addition of RT in these cases increased the rate of CR to 24%. In this group, three of four patients who had active systemic disease responded systemically. Progression free survival was 3 months for both CNS and systemic disease. The median survival of the whole group was 6 months; 1-year survival 32% and 2-year survival 15%. In conclusion, systemic HD-MTX-based combination chemotherapy yields an initial response rate of 100% in the CNS and a 47% concomitant systemic response. A complete CNS response can be obtained prior to RT but this adds little to the overall CR rate. Durable responses are rare. Since both CNS and systemic relapses appear in tandem, future trials should evaluate alternative modalities in order to enhance drug delivery into the CNS.
 ...
PMID:Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. 1200 63

The author reports a rare case of brachial plexus infiltration by non-Hodgkin's lymphoma. T2-weighted MRI showed high signal intensity along the right brachial plexus and soft tissue masses. Ga-67 scintigraphy showed abnormal tracer uptake along the course of the right brachial plexus, and was superior to MRI in detecting the abnormality.
 ...
PMID:A case of non-Hodgkin's lymphoma infiltrating the brachial plexus detected by Ga-67 scintigraphy. 1212 1

Primary central nervous system lymphoma of non-Hodgkin's type are distinguished from systemic non-Hodgkin's lymphoma because of their different pathobiological behaviour. Predisposing factors are pharmacologically induced immunosuppression and those referring to diseases. We present the case of a patient who was sent to hospital in case of emergency due to pain of one half of the face. The symptoms corresponded essentially to neuralgia of the trigeminal nerve. During course other neurological symptoms showed up. The right diagnoses of a primary central nervous system lymphoma of non-hodgkin's type was finally made post mortem. The case especially reveals the difficulties of diagnosis - including negative and confusing MRI-findings - and the variety of differential diagnosis of this also in not immunosuppressed persons more and more frequent kind of tumor.
 ...
PMID:[Neuralgia of the trigeminal nerve as first symptom of a primary central nervous system lymphoma of non-Hodgkin's type]. 1257 69

We report a rare case of malignant lymphopma of the cranial vault. A 71-year-old woman developed an asymptomatic subcutaneous mass on the scalp. The skin over the lesion was normal and the mass was firm and attached to the skull. Neurological examination revealed no abnormalities. Plain CT scans showed a high-density lesion that was widely attached to the skull and the surface of the skull was slightly irregular. About 25 days later, enhanced CT showed that the mass was well enhanced and extended into the cranium, and decalcification of the skull adjacent to the lesion had progressed. MRI showed long T1 and T2 values of the mass and the adjacent bone marrow. Bone scintigraphy and gallium scintigraphy showed prominent accumulation of radioisotopes in the scalp lesion. The mass, dura, and infiltrated bone were resected, and the surface of the brain was found to be intact. Histological examination revealed that the tumor was non-Hodgkin's lymphoma (diffuse, medium-sized, B cell lymphoma). The fact that the tumor first developed extracranially and then extended into the cranium without severe bone destruction and the fact that the dura completely protected the brain surface may indicate that the malignant lymphoma originated from the skull and showed infiltrative growth, while the dura provided a strong barrier to its intracranial extension. Thus, malignant lymphoma originating from the skull may tend to extend outside the cranium first and within the cranium subsequently, as in our case, and this may be the reason why the complaint at presentation of more than half of the reported patients is a scalp mass rather than any neurological sign.
 ...
PMID:[A case of malignant lymphoma of the cranial vault]. 1270 23

The last 25 years have seen major changes in the imaging investigation and subsequent management of patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL); accurate staging is vital for prognostication and treatment in both, and particularly in HD. The choice of imaging modality for staging depends on its accuracy, impact on clinical decision-making, and availability. Modern CT scanners fulfil most of the desired criteria. The advent of CT scanning, along with the development of ever more effective chemotherapeutic regimens, has resulted in the virtual demise of bipedal lymphangiography (LAG) as a staging tool in patients with lymphoma. It has rendered superfluous a battery of other tests that were in routine use. This contribution reviews the evidence for the use of CT in preference to LAG. CT accurately depicts nodal enlargement above and below the diaphragm, has variable sensitivity for intra-abdominal visceral involvement and is generally outstanding in depicting the extent of disease, especially extranodal extension. Despite the advances in CT technology, there are still areas where CT performs less well (e.g. disease in normal-sized lymph nodes, splenic and bone marrow infiltration). The influence of technical factors, such as the use of intravenous contrast medium, is discussed. In some instances, CT is not the imaging modality of choice and the place of newer techniques such as MRI and endoscopic ultrasound will be reviewed.
 ...
PMID:Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. 1270 30


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>